Citi analyst Joel Beatty conducted a survey of 325 U.S. physicians to assess views related to Amarin’s Vascepa. Of the doctors that were “very familiar” with the Reduce-It results, 84% provided positive comments regarding the study, Beatty tells investors in a research note. Further, prior authorization requirements are seen as a “major barrier” to Vascepa use, the analyst adds. He keeps a Buy rating on Amarin.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.